Iațentiuc Andreea, Iațentiuc Iustin Mihai, Frăsinariu Otilia Elena, Cozma Sebastian Romică, Bitere-Popa Oana Roxana, Olariu Raluca, Rădulescu Luminița Mihaela, Ioniuc Ileana, Cuciureanu Magdalena, Alecsa Mirabela, Guma Constantin, Miron Ingrith Crenguța
Departament of Mother and Child Medicine, University of Medicine and Pharmacy Gr. T. Popa, 700115 Iași, Romania.
Doctoral School "Grigore T. Popa" University of Medicine and Pharmacy, University Street, No. 16, 700115 Iasi, Romania.
Int J Mol Sci. 2025 May 16;26(10):4787. doi: 10.3390/ijms26104787.
There is significant inter-individual variability in the prevalence and severity of cisplatin-induced ototoxicity, which is greatly influenced by genetic and non-genetic factors that predispose the patient to the development of hearing loss. Currently, the focus should be on identifying patients who are more likely to develop ototoxicity based on genetic and non-genetic factors, as therapies to combat ototoxicity are limited or still under study. The severity of hearing loss and the time of its onset may be influenced by certain genetic polymorphisms or the dose administered, age, sex, diet, the administration of other drugs with ototoxic potential, and association with radiotherapy of the head and neck. Knowing the risk factors allows the doctor to manage each case in a personalized manner, preventing hearing damage, especially in the long term. With the help of PubMed and Scopus, we searched for relevant studies documenting the genetic and non-genetic risk in patients treated with cisplatin. This review article is a synthesis of the literature that points out the importance of these factors, encouraging genetic screening and improving quality of life in patients treated with cisplatin.
顺铂所致耳毒性的发生率和严重程度存在显著的个体间差异，这在很大程度上受遗传和非遗传因素影响，这些因素使患者易发生听力损失。目前，重点应是基于遗传和非遗传因素识别更易发生耳毒性的患者，因为对抗耳毒性的疗法有限或仍在研究中。听力损失的严重程度及其发生时间可能受某些基因多态性、给药剂量、年龄、性别、饮食、使用其他有耳毒性潜在风险的药物以及与头颈部放疗联合使用的影响。了解这些风险因素可使医生以个性化方式处理每个病例，预防听力损害，尤其是长期损害。借助PubMed和Scopus，我们检索了记录顺铂治疗患者遗传和非遗传风险的相关研究。这篇综述文章是文献的综合，指出了这些因素的重要性，鼓励进行基因筛查并改善顺铂治疗患者的生活质量。
